Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chau, I.
Right arrow Articles by Cunningham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chau, I.
Right arrow Articles by Cunningham, D.
Related Collections
Right arrow Oncology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 64:159-180 (2002)
© 2002 The British Council

Chemotherapy in colorectal cancer: new options and new challenges

Ian Chau and David Cunningham

Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey, UK

Colorectal cancer is the second most common cause of cancer-related mortality in Europe and North America. Studies conducted in the last two decades have established the role of adjuvant therapy in stage III colon cancer. However, there is currently no international consensus with the role of adjuvant treatment in stage II disease. The introduction of irinotecan, oxaliplatin, oral fluoropyrimidines and raltitrexed has broadened the treatment options available for patients with advanced colorectal cancer. The integration of these drugs with the new molecular targeted therapies such as epidermal growth factor receptor, cyclooxygenase, angiogenesis and matrix metalloproteinase inhibition will form the basis of clinical research in the next few years and may, in the future, impact on the survival of patients with colorectal cancer. This review will focus on the place of chemotherapy in colorectal cancer, but not its role in combination with radiotherapy in rectal cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y.-K. Shin, B. C. Yoo, H. J. Chang, E. Jeon, S.-H. Hong, M.-S. Jung, S.-J. Lim, and J.-G. Park
Down-regulation of Mitochondrial F1F0-ATP Synthase in Human Colon Cancer Cells with Induced 5-Fluorouracil Resistance
Cancer Res., April 15, 2005; 65(8): 3162 - 3170.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Zhu, W. Guo, L. Zhang, J. J. Davis, F. Teraishi, S. Wu, X. Cao, J. Daniel, W. R. Smythe, and B. Fang
Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells
Mol. Cancer Ther., March 1, 2005; 4(3): 451 - 456.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Aschele, D. Debernardis, S. Lonardi, R. Bandelloni, S. Casazza, S. Monfardini, and L. Gallo
Deleted in Colon Cancer Protein Expression in Colorectal Cancer Metastases: A Major Predictor of Survival in Patients With Unresectable Metastatic Disease Receiving Palliative Fluorouracil-Based Chemotherapy
J. Clin. Oncol., September 15, 2004; 22(18): 3758 - 3765.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. C. Yoo, E. Jeon, S.-H. Hong, Y.-K. Shin, H. J. Chang, and J.-G. Park
Metabotropic Glutamate Receptor 4-Mediated 5-Fluorouracil Resistance in a Human Colon Cancer Cell Line
Clin. Cancer Res., June 15, 2004; 10(12): 4176 - 4184.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.